Evidence map›Paper›PMID 28592904›Full record

ReviewNature reviews. Neuroscience2017

Non-motor features of Parkinson disease.

Anthony H V Schapira, K Ray Chaudhuri, Peter Jenner

Erratum issued 4 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 996 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
996citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04932434 phase2completednot on this mapstarted 2021, after this paper: background citation

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

TypeinterventionalSponsorJoshua Woolley, MD, PhDRan2021 to 2024Enrolled12ConditionsParkinson Disease, Depression, AnxietyArmsPsilocybin therapy
NCT05483036 completednot on this mapstarted 2022, after this paper: background citation

Perception in Parkinson's Disease

TypeobservationalSponsorBoston University Charles River CampusRan2022 to 2025Enrolled54ConditionsParkinson's Disease, Perception, Visual Hallucination
NCT06293118 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Chronic Effect of Ischemic Conditioning on Motor Function, Cognitive Performance, and Immune System in Individuals With Parkinson's Disease

TypeinterventionalSponsorHospital Israelita Albert EinsteinRan2026 to 2028Enrolled34ConditionsParkinson DiseaseArmsIschemic conditioning group, Sham group
NCT07013513 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Characterising the Physiological Resilience of People With Parkinson's Disease - With Feasibility

Typeobservational_patient_registrySponsorUniversity of NottinghamRan2025 to 2026Enrolled16ConditionsParkinson&#39, s Disease (PD)
3 · Its place in the literature

Who cites it

996 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Limb apraxia in Parkinson's disease and atypical parkinsonian syndromes: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Prevalence and impact of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Baseline peripheral inflammatory profiles predict phenoconversion in prodromal Parkinson's disease: a longitudinal cohort study.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Article
  20. Species-dependent activities of the PINK1-parkin axis.Translational neurodegeneration · 2026
    Review

936 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Anthony H V SchapiraDepartment of Clinical Neurosciences, University College London (UCL) Institute of Neurology, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.
K Ray ChaudhuriNational Parkinson Foundation International Centre of Excellence, King's College Hospital, King's College London, Camberwell Road, London SE5 9RS, UK.
Peter JennerNeurodegenerative Diseases Research Group, Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, Newcomen Street, London SE1 1UL, UK.

Funding

Medical Research Council MR/L501499/1Medical Research Council MR/M006646/1
6 · The paper itself

Abstract

Many of the motor symptoms of Parkinson disease (PD) can be preceded, sometimes for several years, by non-motor symptoms that include hyposmia, sleep disorders, depression and constipation. These non-motor features appear across the spectrum of patients with PD, including individuals with genetic causes of PD. The neuroanatomical and neuropharmacological bases of non-motor abnormalities in PD remain largely undefined. Here, we discuss recent advances that have helped to establish the presence, severity and effect on the quality of life of non-motor symptoms in PD, and the neuroanatomical and neuropharmacological mechanisms involved. We also discuss the potential for the non-motor features to define a prodrome that may enable the early diagnosis of PD.

Indexed as

Prodromal SymptomsBrainConstipationDepressionEarly DiagnosisHumansNeurotransmitter AgentsOlfaction DisordersParkinson DiseaseQuality of LifeSleep Wake DisordersNeurotransmitter Agents

Identifiers

PMID28592904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.